HCP Live
Contagion LiveCGT LiveNeurology LiveHCP LiveOncology LiveContemporary PediatricsContemporary OBGYNEndocrinology NetworkPractical CardiologyRheumatology Netowrk
  • MJHLS Brand Logo

© 2022 MJH Life Sciences™ , NeurologyLive – Clinical Neurology News and Neurology Expert Insights. All rights reserved.

Recent Update on the Oral Management of Relapsing Remitting Multiple Sclerosis (MS)

Heidi Crayton, MD, provides an update on the oral management considerations in patients with relapsing remitting multiple sclerosis.

EP. 1: RRMS Treatment Initiation and Management

June 29th 2022

Heidi Crayton, MD, shares her thoughts surrounding treatment initiation and management considerations in patients with relapsing-remitting multiple sclerosis.

EP. 2: RRMS Treatment Efficacy and Safety Considerations

June 29th 2022

Dr Heidi Crayton reviews treatment efficacy and safety considerations for conventional and novel treatment options for patients with relapsing-remitting multiple sclerosis.

EP. 3: Oral Versus Injection Therapy for Patients With RRMS

July 6th 2022

An expert in neurology provides insight into the considerations of oral versus injectable therapies in patients with multiple sclerosis, highlighting their impact on quality of life, brain volume, and cognitive health.

EP. 4: Cognitive Health and Brain Health Considerations in RRMS

July 6th 2022

Heidi Crayton, MD, comments on cognitive and brain health considerations in patients with multiple sclerosis and shares her experiences with both patients and their caregivers.

EP. 5: Impact of Vaccinations on Immunosuppressive Therapy Efficacy

July 13th 2022

Dr Heidi Crayton reviews the potential impact of vaccinations on immunosuppressive disease-modifying therapy efficacy in patients with multiple sclerosis.

EP. 6: Emerging Therapies and Future Directions for RRMS

July 13th 2022

Heidi Crayton, MD, expresses her optimism for the future of multiple sclerosis and highlights emerging therapies and their impact on the care of patients with multiple sclerosis.